ImmuNext Enters Into a Strategic Partnership With Janssen Pharmaceutica N.V. to Develop Novel Immunotherapies for the Treatment of Cancer  
9/5/2012 9:59:40 AM

LEBANON, N.H.--(BUSINESS WIRE)--ImmuNext, Inc., today announced that it has entered into an agreement with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer.